louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01106664: ONO-7746 Study in Healthy Adult Subject
Official title: A Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study and Food Effect Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-7746 in Healthy Adult Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Adult Subjects
Keywords: ONO-7746
Healthy adult subjects
Lead sponsor: Ono Pharmaceutical Co. Ltd
Sponsor class: INDUSTRY
First posted: 2010-04-20
Enrollment: 72
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary objective of this study is to evaluate the safety and tolerability of NON-7746 in healthy adult subjects. The secondary objectives are to characterize the pharmacokinetic and pharmacodynamic profiles of ONO-7746 and to evaluate the food effect on the PK profile of ONO-7746 when administered with or without a meal.


Eligibility criteria: Inclusion Criteria:

* Healthy non-smoking male or female subjects (18-55 inclusive)
* Body mass index (BMI) of 19-35 kg/m2 (inclusive)
* For females, postmenopausal, non-lactating, and non-pregnant

Exclusion Criteria:

* History or presence of clinically significant disease

Primary outcomes:
measure: Safety Assessment
timeFrame: up to 42 days
Secondary outcomes:
measure: Characterization of PK and PD profiles, including platelet count changes of ONO-7746
timeFrame: up to 42 days
measure: Effect of food on ONO-7746 pharmacokinetics
timeFrame: up to 42 days
Other outcomes:
Locations:
city: Austin
country: United States
facility: Austin Clinical Site
state: Texas
Study officials:
affiliation: Ono Pharmaceutical Co. Ltd
name: Ono Pharma USA, Inc.
role: STUDY_DIRECTOR
References:
Clinical trial NCT00455364: Voriconazole as Prophylactic Therapy in Lung Transplant Recipients
Official title: Assessment of Safety and Efficacy of Voriconazole as Prophylactic Antifungal Therapy for Lung Transplant Recipients
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Infection
Keywords: Fungal infection prophylaxis
Lung transplant
Fungal infection post lung transplant
Lead sponsor: University of Chicago
Sponsor class: OTHER
Collaborators: name: Pfizer
First posted: 2007-04-03
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to compare the safety and efficacy of Voriconazole with Itraconazole following lung transplantation.

Detailed description: All participants will receive itraconazole during their inpatient post transplant stay. As an outpatient, ten subjects will be randomized to receive itraconazole 200mg orally once daily for 6 month and ten patients to receive voriconazole 200mg orally twice daily for 6 months . All subjects will be followed in the clinic as per the standard transplant treatment

Eligibility criteria: Inclusion Criteria:

* Bilateral-lung or single-lung transplant recipients between the ages of 18- 65 years old.
* Patients must be able to give informed consent prior to and again after transplantation

Exclusion Criteria:

* Lung transplant patients unable to give informed consent.
* Prior adverse reaction to the drug itraconazole or voriconazole

Primary outcomes:
measure: Subject will be monitored for any fungal infection throughout the duration of the study.
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: The University of Chicago
state: Illinois
Study officials:
affiliation: University of Chicago
name: Sangeeta Bhorade, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03724864: Edulcorants Effect in Caries Risk Schoolchildren
Official title: Effect of a Daily Dose of Snacks Containing Mannitol or Stevia Rebaudiana as Sweeteners in High Caries Risk Schoolchildren
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dental Caries
Lead sponsor: Università degli Studi di Sassari
Sponsor class: OTHER
First posted: 2018-10-30
Enrollment: 271
Sex: ALL
Minimum age (years): 6
Maximum age (years): 8
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This double-blind RCT aimed to evaluate the effect of sugar-free snacks on caries risk in 6-9 years-old schoolchildren. Considering a 20% difference among groups, the number of subjects needed per group was set in 87. Two-hundred-seventy-one children at risk for caries measured through Cariogram were selected and randomly assigned to three groups consuming twice a day snacks containing Stevia or Maltitol or sugar for 42 days. Parents filled out a standardized questionnaire regarding personal, medical and oral behavioural information. Bleeding on probing, plaque pH and cariogenic microflora were assessed at baseline (t0), after 21 (t1) and 42 days of snacks' use (t2) and 120 days after the end of use (t3). Cariogram was also repeated at t2.


Eligibility criteria: Inclusion Criteria:

* more than 1 initial carious lesion in the enamel (ICDAS 2-3),
* but no manifest lesion in the dentine,
* a salivary MS concentration ≥10\^5 CFU/ml.

Exclusion Criteria:

* Subjects with a history of systemic diseases and antibiotic therapy within 30 days before baseline were excluded.

Primary outcomes:
measure: Caries risk reduction
timeFrame: 42 days
measure: reduction of salivary cariogenic bacteria
timeFrame: 42 days
Secondary outcomes:
measure: modification of the plaque-pH
timeFrame: 42 days
Other outcomes:
Locations:
city: Sassari
country: Italy
facility: Pediatric dentistry dept
Study officials:
References:
Clinical trial NCT01885364: Esmolol Pretreatment on Pain During Injection of Propofol
Official title: Esmolol Pretreatment on Pain During Injection of Propofol
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pain
Keywords: esmolol
pain
propofol
remifentanil
Lead sponsor: Kyungpook National University Hospital
Sponsor class: OTHER
First posted: 2013-06-25
Enrollment: 120
Sex: ALL
Minimum age (years): 19
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Pain on injection of propofol is a common side effect. The present study was designed to investigate the effect of esmolol on pain on propofol injection and to compare it with remifentanil and placebo.

Detailed description: In a double-blind, prospective trial, 120 patients scheduled to undergo elective surgery were randomized to receive normal saline (n=30), remifentanil 0.35 μg/kg (n=30), esmolol 0.5 mg/kg (n=30), or Esmolol 1mg/kg (n=30) as pretreatment. Thirty seconds after pretreatment, 25% of the total calculated dose of propofol (2 mg/kg) was administrated into a dorsal hand vein. Ten seconds after propofol had been given at the rate of 0.5 ml/sec pain was assessed on a four-point scale (0=none, 1 = mild, 2= moderate, 3= severe).

Eligibility criteria: Inclusion Criteria:

* patients aged 19-60 years, American Society of Anesthesiologists (ASA) physical status I and II, scheduled for elective surgery under general anesthesia

Exclusion Criteria:

* Patients with cardiovascular, neurological or psychiatric disorder problem, patients who received the analgesic or sedative medications within the last 24 hours, and pregnancy were excluded

Primary outcomes:
measure: Pain on injection of propofol
timeFrame: 10 seconds after injection of 25% of the total calculated dose of propofol (2 mg/kg)
Secondary outcomes:
Other outcomes:
Locations:
city: Daegu
country: Korea, Republic of
facility: Kyungpook National University Hospital
Study officials:
affiliation: Kyungpook National University Hospital
name: Younghoon Jeon, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02066064: G-Eye Advanced Colonoscopy For Increased Polyp Detection Rate-randomized Tandem Study With Different Endoscopist
Official title: G-Eye Advanced Colonoscopy For Increased Polyp Detection Rate - Randomized Tandem Study With Different Endoscopist
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Colorectal Cancer
Adenoma
Keywords: Colorectal Cancer
Adenoma
Standard Colonoscopy
G-EYE(TM) Colonoscopy
Lead sponsor: Smart Medical Systems Ltd.
Sponsor class: INDUSTRY
First posted: 2014-02-19
Enrollment: 58
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SCREENING

Brief summary: The purpose of this study is to compare the adenoma detection rate of G-EYE™ high definition colonoscopy with that of standard high definition colonoscopy.

Detailed description: Single Center, two-arm, randomized , open-label study with different and blinded endoscopists.

Eligibility criteria: Inclusion Criteria:

1. Patients over 50 years old
2. Referred to colonoscopy for screening, following positive FOBT testing, change of bowel habits or for surveillance colonoscopy (history of adenoma resection).
3. The patient must understand and provide written consent for the procedure.

Exclusion Criteria:

1. Subjects with inflammatory bowel disease;
2. Subjects with a personal history of polyposis syndrome;
3. Subjects with suspected chronic stricture potentially precluding complete colonoscopy;
4. Subjects with diverticulitis or toxic megacolon;
5. Subjects with a history of radiation therapy to abdomen or pelvis;
6. Pregnant or lactating female subjects;
7. Subjects who are currently enrolled in another clinical investigation.
8. Subjects with current oral or parenteral use of anticoagulants
9. Subjects with recent (within the last 3 mounts) coronary ischemia or CVA (stroke)

Primary outcomes:
measure: G-EYE™ colonoscopy detection rate of adenomas and serrated lesions compared to the standard colonoscopy detection rate of the same.
timeFrame: estimated 14 days (following histology results)
Secondary outcomes:
measure: polyp and adenoma detection, procedure times and safety
timeFrame: 24-72 hours post procedure
Other outcomes:
Locations:
city: Frankfurt
country: Germany
facility: St. Marienkrankenhaus Frankfurt
Study officials:
name: Ralf Kiesslich, Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04359264: Direct Income SupporT and Advice Negating Spread of Epidemic COVID-19: a Randomized Controlled Trial
Official title: Direct Income SupporT and Advice Negating Spread of Epidemic COVID-19: a Randomized Controlled Trial (DISTANSE COVID-19 RCT)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: COVID-19
Lead sponsor: Unity Health Toronto
Sponsor class: OTHER
First posted: 2020-04-24
Enrollment: 392
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This is a clinical trial of a cash transfer on symptoms consistent with COVID-19 and adherence to physical distancing guidance.


Eligibility criteria: Inclusion Criteria:

* trouble "making ends meet at the end of the month" due to COVID-19 related disruptions

Exclusion Criteria:

* confirmed positive for COVID-19 based on laboratory testing
* current symptoms consistent with COVID-19

Primary outcomes:
measure: Symptoms consisent with COVID-19
timeFrame: 14 days
Secondary outcomes:
measure: Number of close contacts
timeFrame: Sum of contacts on days 5, 10 and 14
measure: Number of participants with positive test for COVID-19
timeFrame: 14 days
measure: Self-reported health based on the single question: "In general, would you say your health is.."
timeFrame: 14 days
measure: Ability to make ends meet based on the single question: "At the end of the month, are you able to make ends meet?"
timeFrame: 14 days
Other outcomes:
measure: Health care utilization
timeFrame: 14 days
measure: Food security
timeFrame: 14 days
measure: Cost-related medicine non-adherence
timeFrame: 14 days
Locations:
city: Assiginack
country: Canada
facility: Municipality of Assiginack Family Health Team
state: Ontario
city: Toronto
country: Canada
facility: St Michael's Hospital Academic Family Health Team
state: Ontario
Study officials:
References:
citation: Persaud N, Thorpe KE, Bedard M, Hwang SW, Pinto A, Juni P, da Costa BR; DISTANSE COVID-19 (Direct Income SupporT and Advice Negating Spread of Epidemic COVID-19: a randomized controlled trial) study team. Cash transfer during the COVID-19 pandemic: a multicentre, randomised controlled trial. Fam Med Community Health. 2021 Dec;9(4):e001452. doi: 10.1136/fmch-2021-001452.
Clinical trial NCT03581864: Clinical Outcomes of Implantationof Black Diaphragm Intraocular Lens in Complete Aniridia and Aphakia Due to Posttraumatic Eye Rupture
Official title: Clinical Outcomes of Implantationof Black Diaphragm Intraocular Lens in Complete Aniridia and Aphakia Due to Posttraumatic Eye Rupture
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Aphakia Due to Trauma
Eye; Rupture, Traumatic, With Loss of Intraocular Tissue
Aniridia
Keywords: aphakia
black diaphragmintraocular lens
eye rupture
aniridia
Lead sponsor: Medical University of Lublin
Sponsor class: OTHER
First posted: 2018-07-10
Enrollment: 14
Sex: ALL
Minimum age (years): 25
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: consecutive patients

Brief summary: Purpose: To assess long-term outcomes of implantation of black diaphragmintraocular lens (BD IOL) in postraumatic aniridia and aphakia due to eye rupture.

METHODS: This is retrospective consecutive case series of 14 eyes with post-traumatic complete aniridia and aphakia treated withscleral fixation of BD IOL with. Measurements included ophthalmological comorbidities, best corrected visual acuity (BCVA), complications, and postoperative interventions. The average postoperative follow-up period was 36 months.


Eligibility criteria: Inclusion Criteria:

post-traumatic complete aniridia and aphakia

Exclusion Criteria:

active ocluar inflammation or infection

Primary outcomes:
measure: Best-corrected visual acuity
timeFrame: 10 to 120 months
measure: The slit lamp examination
timeFrame: 10 to 120 months
measure: The intrraocular pressure measurement
timeFrame: 10 to 120 months
measure: The medical history
timeFrame: 10 to 120 months
Secondary outcomes:
Other outcomes:
Locations:
city: Lublin
country: Poland
facility: General Department of Ophthalmology in Lublin
Study officials:
References:
Clinical trial NCT02333864: POGO® Automatic Blood Glucose Monitoring System Clinical Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetes Mellitus
Lead sponsor: Intuity Medical, Inc
Sponsor class: INDUSTRY
First posted: 2015-01-07
Enrollment: 287
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: People who are 18 years of age or older and have been diagnosed with diabetes

Brief summary: The purpose of this study is to determine if the POGO® system delivers accurate blood glucose readings in the hands of the lay user and assess the POGO® system accuracy when used by trained health care professionals.

Detailed description: Subjects will review labeling materials and self-test using the POGO® system. An HCP-assisted test also will be performed; both tests will be compared to a fingerstick capillary sample run on a YSI reference glucose analyzer. Subjects will complete questionnaires on labeling comprehension and POGO® usability.

Eligibility criteria: Inclusion Criteria:

* Be diagnosed with diabetes
* Be 18 years of age or older
* Be able to read, write, and understand English fluently
* Be able and willing to give written informed consent and have provided signed, written consent

Exclusion Criteria:

* Any condition which in the opinion of the Investigator may place the subject or site personnel at excessive risk
* A physical condition or limitation that prevents the subject from reading the labeling and using a BGMS on their own
* Previous experience with the POGO® BGMS
* Formal experience with clinical (medical) laboratory equipment or formal training in a relevant medical field

Primary outcomes:
measure: Accuracy Validation of the POGO® BGMS: Minimum outcome of 95% of results within 20% of reference measurement.
timeFrame: Blood glucose measured at time of single visit for each subject, endpoint evaluated at completion of study (approximately four months after initiation.)
measure: Accuracy Verification of the POGO® BGMS: Minimum outcome of 95% of results within 20% of reference measurement.
timeFrame: Blood glucose measured at time of single visit for each subject, endpoint evaluated at completion of study (approximately four months after initiation.)
Secondary outcomes:
Other outcomes:
Locations:
city: Walnut Creek
country: United States
facility: Diablo Clinical Reasearch
state: California
city: Minneapolis
country: United States
facility: Park Nicollett Institute - International Diabetes Center
state: Minnesota
Study officials:
References:
Clinical trial NCT03574064: Effects of Gut Peptides on Bone Remodeling
Official title: Investigation of GLP-2 Mechanism of Action
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Lead sponsor: University of Copenhagen
Sponsor class: OTHER
Collaborators: name: Hvidovre University Hospital
First posted: 2018-06-29
Enrollment: 10
Sex: FEMALE
Minimum age (years): 50
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: We will investigate effects of gut hormones on bone remodeling.


Eligibility criteria: Inclusion Criteria:

Women Age above 50 years Postmenopausal Caucasian BMI 18.5 to 28.0 kg/m2.

Exclusion Criteria:

Smoking Medication believed to influence study outcome Weight change more than 3 kg whitin the last 3 months Overweight surgery Intestinal surgery Hgb\<7,0 mmol/L Decreased renal function

Primary outcomes:
measure: C-terminal telopeptide (CTX). At all time points and AUC(0-240 min).
timeFrame: -10 minutes to 600 minutes
measure: N-terminal propeptide of type 1 procollagen (P1NP). At all time points and AUC(0-240 min).
timeFrame: -10 minutes to 600 minutes
Secondary outcomes:
measure: PTH
timeFrame: -10 minutes to 600 minutes
measure: Sclerostin
timeFrame: -10 minutes to 600 minutes
measure: Calcium
timeFrame: -10 minutes to 600 minutes
measure: Glucose
timeFrame: -10 minutes to 600 minutes
measure: Glucose-dependent insulinotropic polypeptide (GIP)
timeFrame: -10 minutes to 600 minutes
measure: Insulin
timeFrame: -10 minutes to 600 minutes
measure: C-peptide
timeFrame: -10 minutes to 600 minutes
measure: Glukagon-like peptide-1 (GLP-1)
timeFrame: -10 minutes to 600 minutes
measure: Glucagon
timeFrame: -10 minutes to 600 minutes
measure: Glukagon-like peptide-2 (GLP-2)
timeFrame: -10 minutes to 600 minutes
measure: PP
timeFrame: -10 minutes to 600 minutes
Other outcomes:
measure: Blood pressure
timeFrame: -10 minutes to 60 minutes
measure: Heart rate
timeFrame: -10 minutes to 60 minutes
Locations:
city: Hvidovre
country: Denmark
facility: Hvidovre University Hospital
Study officials:
References:
Clinical trial NCT05864664: Safety and Efficacy of Wide Awake Local Anesthesia no Tourniquet Technique (WALANT) in Ankle Removal of Implant Surgery
Official title: Comparing Removal of Ankle Implants/ Hardware Using the Wide-awake Local Anesthesia no Tourniquet (WALANT) Technique Versus General Anesthesia.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Safety Issues
Post Operative Pain
Local Anesthetic Complication
Lead sponsor: Kuwait Institute for Medical Specialization
Sponsor class: OTHER_GOV
First posted: 2023-05-18
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Interventional, prospective, therapeutic, comparative, randomized controlled ?
Primary purpose: PREVENTION

Brief summary: Safety and efficacy of wide awake local anesthesia no torniquet technique (WALANT) in ankle surgery. Studying risks and benefits from WALANT compared to general anesthesia . WALANT expected to decrease in intraoperative/post operative pain at the surgical site and decrease hospital time .


Eligibility criteria: Inclusion Criteria:

* Age: \>18
* Previous ORIF for:
* Unimalleolar fractures
* Bimalleolar fractures
* Trimalleolar fractures

Exclusion Criteria:

* Allergy to local anesthesia
* Psychiatric diagnosis including: affect disorders, uncooperative
* Severe cardiovascular disease

Primary outcomes:
measure: Evaluation of the patient's maximum pain intraoperatively at the surgical site
timeFrame: Intraoperative
measure: Blood loss
timeFrame: Intraoperative
Secondary outcomes:
Other outcomes:
Locations:
city: Kuwait
country: Kuwait
facility: AlRazi Orthopedic Hospital
Study officials:
affiliation: Kuwait University
name: Ali Jarragh, MD FRCS.C
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01314664: A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC)
Official title: A PROSPECTIVE REGISTRY TO ASSESS THE EFFECTIVENESS AND LOCAL TOLERABILITY OF INTRAVESICAL VALRUBICIN IN SUBJECTS WITH NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Bladder Cancer
CIS
Keywords: Non-Muscle Invasive Bladder Cancer
CIS
BCG Refractory
Lead sponsor: Endo Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2011-03-14
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: subjects who will be receiving intravesical valrubicin treatment for NMIBC

Brief summary: The purpose of this study is to observe and describe the effectiveness and local tolerability of intravesical treatment with valrubicin for non-muscle invasive bladder cancer (NMIBC) in a cohort of subjects treated under routine practice conditions.


Eligibility criteria: Inclusion Criteria:

* Males and females 18 years of age and older
* Diagnosed with NMIBC
* Prescribed intravesical valrubicin to treat NMIBC
* Understood and signed Informed Consent to participate

Exclusion Criteria:

* None

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Phoenix
country: United States
facility: BCG Oncology
state: Arizona
city: Hialeah
country: United States
facility: Urology Research Network
state: Florida
city: Vero Beach
country: United States
facility: Advanced Urology Association of Florida
state: Florida
city: Overland Park
country: United States
facility: Kansas City Urology Care
state: Kansas
city: Sewell
country: United States
facility: Delaware Valley Urology
state: New Jersey
city: Voorhees
country: United States
facility: Delaware Valley Urology
state: New Jersey
city: Bethpage
country: United States
facility: Long Island Urological Associates
state: New York
city: Bala-Cynwyd
country: United States
facility: Urologic Consultants of SE PA
state: Pennsylvania
city: Nashville
country: United States
facility: Vanderbilt University Medical Center
state: Tennessee
city: Arlington
country: United States
facility: Urology Associates of North Texas
state: Texas
city: Dallas
country: United States
facility: Urology Clinics of North Texas
state: Texas
Study officials:
affiliation: Endo
name: Todd Kirby, PhD
role: STUDY_DIRECTOR
References: